Annexin Pharmaceuticals AB

Developing Annexin A5 protein to treat vascular, inflammatory, and cancerous diseases.

ANNX | ST

Overview

Corporate Details

ISIN(s):: SE0009664154
LEI:: 5493000JP703HGPJEX27
Country:: Sweden
Address:: KAMMAKARGATAN 48, 111 60 Stockholm
Website:: https://annexinpharma.com/
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Annexin Pharmaceuticals AB is a clinical-stage biotechnology company focused on the therapeutic protein Annexin A5. The company's lead drug candidate, ANXV, is a recombinant human Annexin A5 that targets phosphatidylserine (PS), a lipid exposed on the surface of stressed or damaged cells. By binding to PS, ANXV acts as a cell protector and immunomodulator, counteracting tissue injury and regulating immune responses. The company's primary focus is on developing ANXV for indications with significant unmet medical needs, including Retinal Vein Occlusion (RVO), for which it is currently in Phase 2 clinical trials, and oncology. ANXV has potential as a first-in-class treatment across a broad range of vascular, inflammatory, and cancerous diseases.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Annexin Pharmaceuticals AB filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Annexin Pharmaceuticals AB

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for Annexin Pharmaceuticals AB via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
Elicera Therapeutics AB Develops CAR T-cell & oncolytic virus therapies for cancer, enhanced by its iTANK platform.	Sweden	ELIC
Ellen AB Develops research-based probiotic and prebiotic products for women's intimate health and pH balance.	Sweden	ELN
Enlivex Therapeutics Ltd. Developing cell therapy to restore immune balance for inflammatory diseases like sepsis.	Israel	ENLV
Enorama Pharma AB Develops & makes consumer nicotine products & medicated gums, offering private label solutions.	Sweden	ERMA
ENZYCHEM LIFESCIENCES CORPORATION Develops novel therapeutics and APIs for oncology, inflammation, and respiratory diseases.	South Korea	183490
Enzymatica AB Develops medical devices with patented enzyme technology to treat upper respiratory infections.	Sweden	ENZY
Epi Biotech Co., Ltd. Developing alopecia therapies, skin regeneration products, and preclinical CRO services.	South Korea	446440
EQL Pharma AB Develops and sells cost-efficient niche generic medicines for the Nordic healthcare market.	Sweden	EQL
ERYTECH Pharma S.A. Developing phage therapies to combat antibiotic-resistant bacterial infections.	France	ERYP
EuBiologics Co., Ltd. Develops vaccines for global public health and provides biopharmaceutical CRMO services.	South Korea	206650